{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:14Z","timestamp":1790707214371,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.amjmed.2005.09.054","type":"journal-article","created":{"date-parts":[[2006,2,21]],"date-time":"2006-02-21T07:14:56Z","timestamp":1140506096000},"page":"255-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":260,"title":["Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study"],"prefix":"10.1016","volume":"119","author":[{"given":"Gurkirpal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Fort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Hanrahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso E.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Andrade-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Wallemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naurang M.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Stenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Triadafilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.09.054_bib1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.amjmed.2005.09.054_bib2","first-page":"18","article-title":"Epidemiology of NSAID-induced GI complications","volume":"26","author":"Singh","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis","volume":"325","author":"Deeks","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2005.09.054_bib4","first-page":"445","article-title":"Efficacy of celecoxib versus ibuprofen in the treatment of acute pain","volume":"31","author":"Ekman","year":"2002","journal-title":"Am J Orthop"},{"key":"10.1016\/j.amjmed.2005.09.054_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs","volume":"9","author":"Saag","year":"2000","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/030097402320318431","article-title":"A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis","volume":"31","author":"Geusens","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0149-2918(99)80016-2","article-title":"Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain","volume":"21","author":"Morrison","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2005.09.054_bib8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.09.054_bib10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.09.054_bib11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.09.054_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.09.054_bib14","first-page":"768","article-title":"Osteoarthritis clinical trials","volume":"24","author":"Bellamy","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib15","first-page":"1833","article-title":"Validation study of WOMAC","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib16","unstructured":"Merck Research Laboratories. Vioxx Gastrointestinal Outcomes Research Study. Available at: www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b2_01_merck.pdf. Accessed July 22, 2004."},{"key":"10.1016\/j.amjmed.2005.09.054_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/sim.4780101105","article-title":"A general parametric approach to meta-analysis of randomized clinical trials","volume":"10","author":"Whitehead","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","article-title":"Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs","volume":"325","author":"Mamdani","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2005.09.054_bib19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2005.09.054_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.amjmed.2005.09.054_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib22","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib23","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5223(03)00125-9","article-title":"Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery","volume":"125","author":"Ott","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.amjmed.2005.09.054_bib24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib25","unstructured":"Baraf HSB, Fuentealba C, Greenwald M, et al. Gastrointestinal tolerability and effectiveness of etoricoxib compared to diclofenac sodium in patients with osteoarthritis: a randomized, blinded clinical study (EDGE Trial). Poster presented at the American College of Rheumatology annual meeting, October 19, 2004."},{"key":"10.1016\/j.amjmed.2005.09.054_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","article-title":"Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac","volume":"89","author":"White","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","article-title":"Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2005.09.054_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archinte.163.4.481","article-title":"Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly","volume":"163","author":"Mamdani","year":"2003","journal-title":"Arch Intern Med"},{"issue":"suppl 9","key":"10.1016\/j.amjmed.2005.09.054_bib29","first-page":"S657","article-title":"Risk of acute cardiac events among patients treated with cyclooxygenase-2 selective and non-selective-nonsteroidal anti-inflammatory drugs","volume":"50","author":"Campen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.09.054_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-142-3-200502010-00005","article-title":"Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction","volume":"142","author":"Kimmel","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","article-title":"COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"360","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.09.054_bib32","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.0000127578.21885.3E","article-title":"Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults","volume":"109","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.09.054_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib34","unstructured":"http:\/\/www.fda.gov\/cder\/drug\/infopage\/celebrex\/celebrex-hcp.pdf. Accessed January 12, 2005."},{"key":"10.1016\/j.amjmed.2005.09.054_bib35","unstructured":"http:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/Naproxen-hcp.pdf. Accessed January 12, 2005."},{"key":"10.1016\/j.amjmed.2005.09.054_bib36","first-page":"107","article-title":"Selective COX-2 inhibition improves endothelial function in coronary artery disease","volume":"28","author":"Chenevard","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2005.09.054_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2004.10.001","article-title":"Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification","volume":"177","author":"Walter","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2005.09.054_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.09.054_bib39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bmj.315.7119.1333","article-title":"Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure","volume":"315","author":"MacDonald","year":"1997","journal-title":"BMJ"},{"issue":"Suppl","key":"10.1016\/j.amjmed.2005.09.054_bib40","first-page":"B15","article-title":"The effect of exposure duration on NSAID-related serious gastrointestinal adverse event rates","volume":"18","author":"Schaffer","year":"2003","journal-title":"J Gastroentrol Hepatol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305009137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305009137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:40:19Z","timestamp":1757580019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305009137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0002934305009137"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.054","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}